Ombowstring, I think there is a basic difference between the way you and I interpret Varney's use of the word 'financing'. I very much believe that he was referring only to the raising of capital through means that do not involve any licensing agreements for use of their compounds or partnerships with other pharmaceutical companies. I believe that when he mentioned unfavorable terms, he was only referring to to the terms that they could negotiate in a PIPE or other methods of getting money through the capital markets. I do not interpret his comment 'terms are not too favorable' as any way related to their attempts at licensing or partnering any of their compounds. Karl
Market Data 
Markets 
AI
